Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cleveland Research Downgrades Roku to Neutral

Cleveland Research Downgrades Roku to Neutral

Cleveland Research downgrades Roku (NASDAQ:ROKU) from Buy to Neutral.

byBenzinga Newsdesk

October 26, 2022

1 minute read

Cleveland Research downgrades Roku (NASDAQ:ROKU) from Buy to Neutral.

NanoVibronix Presents UroShield Clinical Study At The University Of Michigan

By Benzinga Newsdesk

May 22, 8:36 AM

NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced

NAOV

News

Standard BioTools Announces Collaboration Agreement With Visikol To Offer Multiplex Imaging Mass Cytometry Services

By Benzinga Newsdesk

October 11, 2:31 PM

https://investors.fluidigm.com/news-releases/news-release-details/standard-biotools-announces-collaboration-agreement-visikol

LAB

Cantor Fitzgerald Initiates Coverage On Precigen with Overweight Rating, Announces Price Target of $7

By Benzinga Newsdesk

November 18, 8:43 AM

Cantor Fitzgerald analyst Jennifer Kim initiates coverage on Precigen (NASDAQ:PGEN) with a Overweight rating and announces Price Target of $7.

PGEN

Amylyx Pharmaceuticals Announces Launch Of Public Offering Of 6M Shares Of Common Stock

By Benzinga Newsdesk

October 4, 4:24 PM

Amylyx Pharmaceuticals, Inc. ("Amylyx") today announced the launch of an underwritten public offering of 6,000,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S.

AMLX

Cleveland Research Downgrades Roku to Neutral

Related Posts

NanoVibronix Presents UroShield Clinical Study At The University Of Michigan

Standard BioTools Announces Collaboration Agreement With Visikol To Offer Multiplex Imaging Mass Cytometry Services

Cantor Fitzgerald Initiates Coverage On Precigen with Overweight Rating, Announces Price Target of $7

Amylyx Pharmaceuticals Announces Launch Of Public Offering Of 6M Shares Of Common Stock